Table 2 Association between Ki67 labeling index and clinicopathological findings.

From: TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors

Ki67 labeling index

<5% (1)

5–10% (2)

>10% (3)

p-value (1 vs 2)

p-value (2 vs 3)

p-value (1 vs 3)

Number of cases

304 (77.0%)

68 (17.2%)

23 (5.8%)

   

Age (mean ± s.d.)

51.2 ± 15.2

48.7 ± 17.4

52.5 ± 19.5

0.622 a

0.793 a

0.985 a

Sex (F/M, % male)

255/47 (15.5%)

61/7 (10.3%)

18/5 (21.7%)

ns b

ns b

ns b

Tumor size (mean ± s.d.)

20.8 ± 12.7

22.9 ± 13.1

29.5 ± 20.1

0.548 a

0.380 a

0.144 a

LN metastasis

190/303 (62.7%)

43/68 (63.2%)

16/23 (69.6%)

ns b

ns b

ns b

Distant metastasis d

3 (1.0%)

1 (1.5%)

2 (8.7%)

ns b

ns b

ns b

Stage c

   

ns b

ns b

ns b

 

I

128

35

9

   

II

8

0

0

III

115

23

5

IV

53

10

9

Ex

212 (69.7%)

56 (82.4%)

17 (73.9%)

ns b

ns b

ns b

  1. ns: not significant, p ≥ 0.05.
  2. aNon-parametric ANOVA with Dunnett post hoc test.
  3. bMultiple comparison test for proportions (using the COMPROP procedure in SAS http://www2.sas.com/proceedings/sugi31/204-31.pdf).
  4. cCalculations for Stage (I + II) vs. (III + IV).
  5. dAll metastatic sites were the lung.